Barclays Cuts Prelude to Underweight, Cites Lack of Near-term Catalysts
Barclays Sticks to Its Hold Rating for Prelude Therapeutics (PRLD)
Buy Rating Affirmed for Prelude Therapeutics on Strong Financials and Promising Clinical Prospects
Prelude Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Prelude Therapeutics (PRLD)
H.C. Wainwright Cuts Prelude Therapeutics to Neutral, Cites Valuation
Prelude Therapeutics Analyst Ratings
Prelude Therapeutics Stock Downgraded to Neutral Amid Anticipation for Trial Results
Barclays Sticks to Its Hold Rating for Prelude Therapeutics (PRLD)
Morgan Stanley Downgrades Prelude Therapeutics to Underweight, Lowers Price Target to $4
Prelude Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $5
Prelude Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $6
Prelude Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $17 Price Target
Prelude Therapeutics Analyst Ratings
H.C. Wainwright Sticks to Its Buy Rating for Prelude Therapeutics (PRLD)
Morgan Stanley Reiterates Equal-Weight on Prelude Therapeutics, Maintains $10 Price Target
Prelude Therapeutics Analyst Ratings